Sunshine Biopharma (NASDAQ:SBFM) has filed its Form 10-K for the fiscal year ended December 31, 2025, reporting a steady increase in top-line revenue alongside a significant expansion of its generic drug portfolio.
The company generated $36.31 million in revenue for 2025, representing a 4.1% increase compared to the previous year.
This growth was accompanied by a rise in gross profit, which reached $12.26 million.
Despite the revenue gains, Sunshine Biopharma reported a widened net loss of $5.98 million, influenced in part by a $1.75 million non-cash impairment charge recorded during the fiscal year.
A primary driver of the company’s 2025 operational momentum was the launch of nine new generic drugs.
This expansion of the product pipeline is part of Sunshine Biopharma’s broader strategy to diversify its revenue streams within the competitive pharmaceutical landscape.
To support these initiatives and bolster its balance sheet, the company successfully raised $2.46 million through a registered direct offering.
Looking ahead to 2026, management has announced an aggressive efficiency plan.
The company intends to implement cost reductions of approximately $2 million to $3 million over the next twelve months.
These measures are designed to streamline operations and narrow the net loss as the company scales its newly launched generic offerings.